Scarica l'app Stockscreener
24.62
7.60%
1.74
Dopo l'orario di chiusura:
25.00
0.38
+1.54%
Precedente Chiudi:
$22.88
Aprire:
$23.62
Volume 24 ore:
1.08M
Relative Volume:
0.84
Capitalizzazione di mercato:
$2.03B
Reddito:
-
Utile/perdita netta:
$-154.65M
Rapporto P/E:
-10.35
EPS:
-2.3786
Flusso di cassa netto:
$-142.43M
1 W Prestazione:
+3.01%
1M Prestazione:
-15.77%
6M Prestazione:
-36.07%
1 anno Prestazione:
+46.72%
Intervallo 1D:
$23.59
$24.64
Intervallo di 1 settimana:
$22.42
$24.64
Portata 52W:
$10.44
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Nome
Mineralys Therapeutics Inc
Settore
Industria
Telefono
(888) 378-6240
Indirizzo
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
24.62 | 1.89B | 0 | -154.65M | -142.43M | -2.3786 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-11 | Iniziato | Jefferies | Hold |
| 2024-07-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-02 | Iniziato | Goldman | Buy |
| 2023-03-07 | Iniziato | BofA Securities | Buy |
| 2023-03-07 | Iniziato | Credit Suisse | Outperform |
| 2023-03-07 | Iniziato | Evercore ISI | Outperform |
| 2023-03-07 | Iniziato | Guggenheim | Buy |
| 2023-03-07 | Iniziato | Stifel | Buy |
| 2023-03-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Mineralys Therapeutics Inc Borsa (MLYS) Ultime notizie
Mineralys reports 2025 results, advances hypertension drug review - MSN
Mineralys Therapeutics names Jeffrey Munsie as chief legal officer By Investing.com - Investing.com Australia
Biopharma Co. Gives New CLO $3.6 Million In Stock Awards - Law360
Mineralys Therapeutics grants inducement equity awards to two new employees - MSN
Mineralys Therapeutics appoints Jeffrey Munsie as chief legal officer - TipRanks
Mineralys Grants Inducement Equity Awards to New Employee - MyChesCo
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer - citybiz
Mineralys Therapeutics names Jeffrey Munsie as chief legal officer - Investing.com
Mineralys Therapeutics appoints Jeffrey A. Munsie as chief legal officer - marketscreener.com
Mineralys brings in veteran biotech lawyer as it advances lorundrostat - Stock Titan
Mineralys Therapeutics (MLYS) Is Down 8.1% After Narrowed Loss, FDA Lorundrostat NDA AcceptanceWhat's Changed - simplywall.st
Hudson Bay Capital Management LP Invests $2.87 Million in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Earnings Beat: Whats the profit margin of Mineralys Therapeutics IncQuarterly Risk Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Growth Value: What is the implied volatility of Mineralys Therapeutics Inc2026 Major Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Is It Time To Reassess Mineralys Therapeutics (MLYS) After The Recent Share Price Pullback? - Yahoo Finance
Mineralys (MLYS) Q4 2025 Earnings Call Transcript - AOL.com
Why Mineralys Therapeutics Shares Are Sliding Today - TipRanks
Research Analysts Issue Forecasts for MLYS Q1 Earnings - MarketBeat
Rodman David Malcom sells Mineralys Therapeutics (MLYS) stock for $10,696 - Investing.com Canada
Insider sale notices at Mineralys Therapeutics (NASDAQ: MLYS) detail multiple Q1 2026 transactions - Stock Titan
Mineralys Therapeutics (MLYS) CMO exercises stock options and sells shares - Stock Titan
Mineralys Reports 2025 Results, Advances Hypertension Drug Review - MyChesCo
Risk Check: Will Mineralys Therapeutics Inc outperform tech stocksTrade Volume Report & Growth-Oriented Investment Plans - baoquankhu1.vn
HC Wainwright Has Positive Outlook of MLYS FY2029 Earnings - MarketBeat
Holocene Advisors LP Buys Shares of 1,205,377 Mineralys Therapeutics, Inc. $MLYS - MarketBeat
David Malcom Rodman Sells 14,058 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
David Malcom Rodman Sells 6,348 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Mineralys Therapeutics MLYS CMO sells shares worth $542,973 By Investing.com - Investing.com Canada
Mineralys Therapeutics CMO Sells Over 20,000 Shares - TradingView
Mineralys targets December 2026 lorundrostat approval as payer engagement and data drive launch strategy - MSN
Mineralys (MLYS) CMO exercises options, sells 20,406 shares under 10b5-1 plan - Stock Titan
Mineralys Therapeutics reports inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Mineralys hire gets stock options and RSUs vesting over four years - Stock Titan
Mineralys: Advancing Lorundrostat Toward Commercialization in Uncontrolled Hypertension With Differentiated Efficacy and Safety - TipRanks
HighVista Strategies LLC Boosts Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Farallon Capital Management LLC Purchases Shares of 1,673,053 Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Cinctive Capital Management LP Has $2.72 Million Stock Holdings in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Reports Strong Phase 3 Results for Lorundrostat in High-Risk Hypertension Patients - MSN
Boothbay Fund Management LLC Increases Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics, Inc. $MLYS Shares Sold by 22NW LP - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Upgraded to Hold at Wall Street Zen - MarketBeat
Losartan Side Effects You Shouldn’t Ignore—Plus One That May Actually Help - AOL.com
Mineralys Therapeutics, Inc. $MLYS Shares Purchased by Suvretta Capital Management LLC - MarketBeat
Integral Health Asset Management LLC Lowers Stake in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics (MLYS) makes progress with FDA for hypertension - MSN
Mineralys Therapeutics Charts Path After NDA Acceptance - TipRanks
Jefferies Maintains MLYS at Hold for Mineralys Therapeutics, Inc. March 2026 - Meyka
David Rodman sells multiple Mineralys (NASDAQ: MLYS) share tranches in Q1 2026 - Stock Titan
Mineralys Therapeutics Inc Azioni (MLYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):